News

Minimal residual disease, a measurement that shows a low level of disease detected, should be used as an endpoint in myeloma clinical trials, a study exploring previously published data suggests. The study, “Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A…

Janssen Biotech has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand Darzalex (daratumumab) to include patients with multiple myeloma. The application seeks approval for Darzalex use in combination with Revlimid (lenalidomid) and Decadron (dexametasone), or Velcade (bortezomib) and Decadron, in…

Patients with heavily treated multiple myeloma have promising response rates when treated with a combination of selinexor (KPT-330) and low-dose dexamethasone, according to the results of a Phase 2b clinical trial. Selinexor, a first-in-class oral selective inhibitor of nuclear export, is currently being developed for a variety of advanced hematologic…

With advances in treatment for multiple myeloma, some studies have reported improved survival rates, especially among young white patients and, to a lesser extent, in patients of other ethnicities. But in a recent study, researchers at the University of Alabama at Birmingham show that these differences are not due to race…

Adding Darzalex (daratumumab) to the treatment of multiple myeloma with Velcade (bortezomib) and dexamethasone significantly improved progression-free survival in a clinical trial of patients who had relapsed or did not respond to standard treatment. The study, “Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma,” published in the…

Empliciti (elotuzumab), a monoclonal antibody, is approved in both the U.S. and Europe as a treatment, in combination with Revlimid (lenalidomide) and Decatron (dexamethasone), for multiple myeloma patients who have received at least one prior treatment. But the German Institute for Quality and Efficiency in Health and Care (IQWiG) announced  that an early benefit assessment was unable to…

Juno Therapeutics and privately held biotech Eureka Therapeutics have entered into an immunotherapy development partnership with Memorial Sloan Kettering Cancer Center (MSK) of New York City. The exclusive license agreement is for joint development of a novel fully-human binding domain targeting B-cell maturation antigen (BCMA), and binding…

Elotuzumab in combination with bortezomib and dexamethasone prolongs the progression free survival of patients with relapsed or refractory multiple myeloma (RRMM), according to the study “Randomized phase 2 study of elotuzumab plus bortezomib/dexamethasone (Bd) versus Bd for relapsed/refractory multiple myeloma,” recently published in Blood. Current choices…

The Multiple Myeloma Research Foundation (MMRF) and the University of Michigan have partnered to provide multiple myeloma patients and their doctors access to personal genomic information which can help guide treatments based on genomic alterations. Over the course of the two-year Molecular Profiling Initiative (MPI), the two institutions aim…

In a video posted on Healio’s Hematology-Oncology page, Dr. Ola Landgren, chief of the myeloma service at Memorial Sloan Kettering Cancer Center in New York City, speaks about new treatments and ongoing discoveries in the field of multiple myeloma. A lot is taking place, quickly, according to Landgren. “I…